Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Beluga Health vs ReadyRx

Beluga Health
Graded #430

Lower grade

vs+12
ReadyRx
Graded #156

Higher grade

The verdict

ReadyRx takes it — 67.8/100 to 55.8/100.

ReadyRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ReadyRx (readyrx.com) is a LegitScript-certified US telehealth provider offering compounded semaglutide from $179/mo and compounded tirzepatide from $255/mo, plus NAD+, sermorelin, glutathione, MIC+B12, and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueReadyRx +16
45
61
Dose & formulationReadyRx +24
40
64
Clinical oversightReadyRx +3
76
79
Labs & monitoringReadyRx +2
62
64
FulfillmentReadyRx +19
64
83
Contract termsEven
55
55
Beluga Health · left barReadyRx · right bar

The numbers

MetricBeluga HealthReadyRx
WeighScore55.8/10067.8/100
GradeCC
Scorecard rank#430#156
SemaglutideNot disclosed$179/mo (starting dose, compounded)
TirzepatideNot disclosed$255/mo (starting dose, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Beluga Health

Graded #430 · C

Strengths

  • Supports GLP-1 care with compounded semaglutide and tirzepatide
  • Board-certified providers and a 50-state medical infrastructure
  • LegitScript certified with SOC 2 and ISO 27001 security
  • Pharmacies follow FDA/USP standards with third-party batch testing
  • Powers many DTC brands as a turnkey telehealth backbone

Where it loses points

  • White-label B2B group, not a direct consumer-facing service
  • Offers compounded, not FDA-approved branded, GLP-1s
  • No public consumer pricing for the GLP-1 offering
  • Cited among nationwide groups tied to FDA telehealth GLP-1 scrutiny
  • Care quality varies by the consumer brand using the platform
ReadyRx

Graded #156 · C

Strengths

  • LegitScript Certified — verifiable via the badge link in the footer
  • Batch lab testing covers the right QA metrics for injectables: potency, sterility, pH, and endotoxicity
  • Pricing shown publicly: $179/mo semaglutide, $255/mo tirzepatide

Where it loses points

  • Pharmacy partners not named — only described as 'FDA-registered compounding pharmacies'
  • Clinicians described as licensed and board-certified, but no names or credentials published
  • 5,000+ member figure comes from a directory listing, not an independent audit

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard